A Multidisciplinary Approach to the Treatment of Inoperable Locally Advanced Breast Cancer with a Fungating Wound: A Case Report and Literature Review
pdf (Русский)

Keywords

locally advanced breast cancer
systemic inflammatory response syndrom
febrile neutropenia prophylaxis
fungating wound
tumor destruction
chemotherapy

How to Cite

Gronskaia, Y. A., Dyakonenko, Z. V., Murskikh, A. D., & Dashyan, G. A. (2024). A Multidisciplinary Approach to the Treatment of Inoperable Locally Advanced Breast Cancer with a Fungating Wound: A Case Report and Literature Review. Voprosy Onkologii, 70(1), 113–118. https://doi.org/10.37469/0507-3758-2024-70-1-113-118

Abstract

Introduction. Locally advanced breast cancer accounts for 5-10 % of all cases of breast cancer in economically developed countries. A particularly rare group of such patients comprises women with significant local tumor growth leading to infiltration of the breast skin, neoplastic ulcerations, tumor lysis and secondary infection. This type of tumor is often accompanied by edema, necrosis, fetid odor, profuse exudate, pain, bleeding and symptoms of infection. Treatment of such cases is difficult, complex, and requires a multidisciplinary approach.

Case description. The article presents a clinical case of a patient with a long-term untreated triple-negative breast cancer, which led to an inoperable locally advanced cancer with large tumor mass, neoplastic fungating wounds, bleeding, and systemic inflammatory response syndrome. Against the background of antibacterial therapy, prevention of tumor lysis syndrome, primary prophylaxis of febrile neutropenia, the patient was started neoadjuvant chemotherapy for vital indications. After completion of the treatment with weekly paclitaxel + carboplatin regimen (12 cycles) and dose-dense AC regimen (4 cycles), a good clinical response was achieved, the complications were fully relieved, and the patient underwent radical surgery. The histological report showed a complete pathomorphological response. Currently, the patient is in remission. This case illustrates the success in a multidisciplinary treatment of a statistically difficult to manage condition with poor prognosis. The literature review shows the main treatment approaches for this group of patients.

https://doi.org/10.37469/0507-3758-2024-70-1-113-118
pdf (Русский)

References

Bogusevicius A., Cepuliene D., Sepetauskiene E. The integrated evaluation of the results of oncoplastic surgery for locally advanced breast cancer. Breast J. 2014; 20: 53-60.-DOI: https://doi.org/10.1111/tbj.12222. URL: https://onlinelibrary.wiley.com/doi/10.1111/tbj.12222.

Alexander S. Malignant fungating wounds: epidemiology, aetiology, presentation and assessment. J Wound Care. 2018; 18(7): 273-4, 276-8, 280.-DOI: https://doi.org/10.12968/jowc.2009.18.7.43110. URL: https://www.magonlinelibrary.com/doi/abs/10.12968/jowc.2009.18.7.43110.

Da Costa Santos C.M., de Mattos Pimenta C.A., Nobre M.R.C. A systematic review of topical treatments to control the odor of malignant fungating wounds. J Pain Symptom Manage. 2010; 39: 1065-1076.-DOI: https://doi.org/10.1016/j.jpainsymman.2009.11.319. URL: https://www.jpsmjournal.com/article/S0885-3924(10)00246-0/fulltext.

Tsichlakidou A., Govina O., Vasilopoulos G., et al. Intervention for symptom management in patients with malignant fungating wounds - a systematic review. J BUON. 2019; 24: 1301-1308. URL: https://pubmed.ncbi.nlm.nih.gov/31424694/.

Specht J., Gralow J.R. Neoadjuvant chemotherapy for locally advanced breast cancer. Semin Radiat Oncol. 2009; 19(4): 222-8.-DOI: https://doi.org/10.1016/j.semradonc.2009.05.001. URL: https://www.sciencedirect.com/science/article/abs/pii/S1053429609000423?via%3Dihub.

Leadbeater M. Assessment and treatment of fungating, malodorous wounds. Br J Community Nurs. 2016; 21: 6-10.-DOI: https://doi.org/10.12968/bjcn.2016.21.Sup3.S6. URL: https://www.magonlinelibrary.com/doi/abs/10.12968/bjcn.2016.21.Sup3.S6.

Tandler S., Stephen-Haynes J. Fungating wounds: management and treatment options. Br J Nurs. 2017; 26: 6-14.-DOI: https://doi.org/10.12968/bjon.2017.26.12.S6. URL: https://www.magonlinelibrary.com/doi/abs/10.12968/bjon.2017.26.12.S6.

Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N Engl J Med. 2010; 363: 1938-48.-DOI: https://doi.org/10.1056/NEJMra1001389. URL: https://www.nejm.org/doi/full/10.1056/NEJMra1001389.

Bear H.D., Anderson S., Brown A., et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003; 21(22): 4165-4174.-DOI: https://doi.org/10.1200/JCO.2003.12.005. URL: https://ascopubs.org/doi/10.1200/JCO.2003.12.005.

Sikov W.M., Berry D.A., Perou C.M., et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015; 33(1): 13-21.-DOI: https://doi.org/10.1200/JCO.2014.57.0572. URL: https://ascopubs.org/doi/10.1200/JCO.2014.57.0572.

Von Minckwitz G., Schneeweiss A., Loibl S., et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014; 15(7): 747-756.-DOI: https://doi.org/10.1016/S1470-2045(14)70160-3. URL: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70160-3/fulltext.

Kuderer N.M., Dale D.C., Crawford J., Lyman G.H. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007; 25(21): 3158-67.-DOI: 10.1200/JCO.2006.08.8823. URL: https://ascopubs.org/doi/10.1200/JCO.2006.08.8823.

Gemici C. Tumour lysis syndrome in solid tumours. Clin Oncol. 2006; 18(10): 773-80.-DOI: https://doi.org/10.1016/j.clon.2006.09.005. URL: https://www.clinicaloncologyonline.net/article/S0936-6555(06)00356-6/fulltext.

Bertrand C., Arnold A., Ching-Hon P., et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008; 26(16): 2767-78.-DOI: https://doi.org/10.1200/JCO.2007.15.0177. URL: https://ascopubs.org/doi/10.1200/JCO.2007.15.0177.

Mott F.E., Esana A., Chakmakjian C., Herrington J.D. Tumor lysis syndrome in solid tumors. Support Cancer Ther. 2005; 2: 188-191. -DOI: https://doi.org/10.3816/SCT.2005.n.012. URL: https://www.sciencedirect.com/science/article/abs/pii/S1543291213600582?via%3Dihub.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2024